Bavarian Nordic Reports Mixed Q1 2026: Travel Health Grows, Public Preparedness Dips
Event summary
- Q1 2026 revenue DKK 1.058B, down 22% YoY from DKK 1.347B in Q1 2025, driven by a 53% drop in Public Preparedness revenue.
- Travel Health revenue up 14% YoY to DKK 721M, fueled by rabies vaccine demand and chikungunya vaccine launches.
- Share buyback program completed with DKK 350M in repurchases, part of a DKK 500M plan for 2026.
- CEO Paul Chaplin to step down by end of 2026, with successor search underway.
- Upgraded full-year revenue guidance to DKK 5.5B–5.7B (from DKK 5B–5.2B) after USD 97M U.S. government contract option.
The big picture
Bavarian Nordic's Q1 2026 results highlight the volatility in its Public Preparedness segment, which remains dependent on outbreak cycles. The company's focus on Travel Health growth—particularly through rabies and chikungunya vaccines—aligns with broader trends in travel-related vaccine demand. The upgraded full-year guidance suggests confidence in securing additional U.S. government contracts, but the leadership transition introduces uncertainty in execution.
What we're watching
- Travel Health Expansion
- Whether Bavarian Nordic can sustain 14% YoY growth in Travel Health amid chikungunya vaccine rollouts in new markets like Switzerland and Brazil.
- Public Preparedness Volatility
- The pace at which Public Preparedness revenue stabilizes after a 53% QoQ drop, as the business normalizes without mpox outbreak impacts.
- Leadership Transition
- How the CEO succession process affects strategic initiatives, particularly the chikungunya vaccine's global expansion and U.S. government contracts.
Related topics